The CDK4/6 inhibitor in HR-positive advanced breast cancer
2018
AbstractBackground:Recently, several high-quality clinical randomized controlled trials (RCTs) have identified that cyclin-dependent kinases (CDKs) 4/6 inhibitors obtained a great safety and efficacy, which can be consequently applied as a combination therapy with letrozole or fulvestrant for women
Keywords:
- Correction
- Cite
- Save
- Machine Reading By IdeaReader
0
References
2
Citations
NaN
KQI